miR-146a rs291064 Identified as Risk Factor for Gastric Cancer
the Cancer Therapy Advisor take:
Investigators found an association between miR-146a rs291064 and risk of gastric cancer (GC) development, according to an article published online in the journal European Journal of Cancer Care.
The authors performed a meta-analysis using PubMed and China National Knowledge Infrastructure searches in order to find relevant studies published before July 2014.
In total, seven case-control studies were chosen for the data analysis, including 3,283 cases and 4,535 controls.
Results showed a significant correlation between the genetic polymorphism miR-146a rs291064 and risk of GC under all genetic models (CC vs. GG, OR=0.76, 95% CI: 0.66, 0.87; CC vs. GC+GG, OR=0.84, 95% CI: 0.71, 0.99; CC+GC vs. GG, OR=0.82, 95% CI: 0.73, 0.91).
Furthermore, the authors conducted subgroup analysis by ethnicity and identified an association in Asian that was determined to be statistically significant.
Investigators found an association between miR-146a rs291064 and risk of gastric cancer development.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Everolimus Maintains Quality of Life in Neuroendocrine Tumors
- High Dose Vitamin B Supplements Should Not Be Taken for Lung Cancer Prevention
- Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection